Welcome to LookChem.com Sign In|Join Free
  • or
6-bromo-2-ethyl-3-(3,5-dibromo-4-hydroxybenzoyl)benzofuran is a chemical compound characterized by its molecular structure that features a benzofuran core with bromine atoms and a substituted benzoyl group. It is an impurity found in benzbromarone, a medication used for treating gout.

1402819-05-9

Post Buying Request

1402819-05-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1402819-05-9 Usage

Uses

Used in Pharmaceutical Industry:
6-bromo-2-ethyl-3-(3,5-dibromo-4-hydroxybenzoyl)benzofuran is used as an impurity in the production of benzbromarone (B185200) for the treatment of gout. Its presence in the final product may affect the efficacy and safety profile of the medication, thus requiring monitoring and control during the manufacturing process.

Check Digit Verification of cas no

The CAS Registry Mumber 1402819-05-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,0,2,8,1 and 9 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1402819-05:
(9*1)+(8*4)+(7*0)+(6*2)+(5*8)+(4*1)+(3*9)+(2*0)+(1*5)=129
129 % 10 = 9
So 1402819-05-9 is a valid CAS Registry Number.

1402819-05-9Downstream Products

1402819-05-9Relevant academic research and scientific papers

Metabolic epoxidation is a critical step for the development of benzbromarone-induced hepatotoxicity

Wang, Wenbao,Wang, Shaojie,Zhang, Tingjian,Lan, Qunsheng,Pang, Jianxin,Wang, Hui,Peng, Ying,Zhao, Huimin,Zhao, Yufei,Wang, Xu,Zheng, Jiang

, p. 1354 - 1363 (2017)

Benzbromarone (BBR) is effective in the treatment of gout; however, clinical findings have shown it can also cause fatal hepatic failure. Our early studies demonstrated that CYP3A catalyzed the biotransformation of BBR to epoxide intermediate(s) that reacted with sulfur nucleophiles of protein to form protein covalent binding both in vitro and in vivo. The present study attempted to define the correlation between metabolic epoxidation and hepatotoxicity of BBR by manipulating the structure of BBR. We rationally designed and synthesized three halogenated BBR derivatives, fluorinated BBR (6-F-BBR), chlorinated BBR (6-Cl-BBR), and brominated BBR (6-Br-BBR), to decrease the potential for cytochrome P450-mediated metabolic activation. Both in vitro and in vivo uricosuric activity assays showed that 6-F-BBR achieved favorable uricosuric effect, while 6-Cl-BBR and 6-Br-BBR showed weak uricosuric efficacy. Additionally, 6-F-BBR elicited much lower hepatotoxicity in mice. Fluorination of BBR offered advantage to metabolic stability in liver microsomes, almost completely blocked the formation of epoxide metabolite(s) and protein covalent binding, and attenuated hepatic and plasma glutathione depletion. Moreover, the structural manipulation did not alter the efficacy of BBR. This work provided solid evidence that the formation of the epoxide(s) is a key step in the development of BBR-induced hepatotoxicity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1402819-05-9